Immutep and Lonza sign agreement for cell line selection, cell banking and process development of ImmuFact(R) IMP321
Immutep and Lonza announced an agreement for cell line selection, master cell banking and process development of ImmuFact(R) IMP321. Lonza will initiate the process development for Immutep’s lead product, using Immutep's newly-developed proprietary cell lines. Immutep announced Phase I/II results for IMP321 in an oral presentation at ASCO (American Society of Clinical Oncology conference) in 2010 describing its use in a chemo-immunotherapy protocol in first-line metastatic breast cancer.
“We are pleased to support Immutep’s development initiatives,” said Janet White, head of Lonza development services. “This partnership directly reflects Lonza’s commitment to emerging biotechnology innovation through its clinical milestones.”
IMP321 (LAG-3Ig) has potential for the treatment of advanced cancer in combination with standard first-line chemotherapy. IMP321 is an antigen presenting cell (APC) activator. Tumour-specific memory CD8 T cells are activated by these APC and contribute to tumour regression.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.